2-isobutyl-benzofuran | 32931-92-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: 2-isobutyl-benzofuran
• 英文别名: 2-(2-Methylpropyl)-1-benzofuran
• CAS: 32931-92-3
• 化学式: C₁₂H₁₄O
• 分子量: 174.243
• InChiKey: RSWLVRNRQZHPMY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  13.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2-(2-methylprop-2-enyl)-1-benzofuran 、 三乙基硅烷 、 三氟乙酸 以50%的产率得到
  参考文献：
  名称：

  ANISIMOV A. V.; LUZIKOV YU. N.; NIKOLAEV V. M.; VIKTOROVA E. A., ZH. ORGAN. XIMII, 1979, 15, HO 1, 172-174

  摘要：

  DOI：

文献信息

• Dioxanes and uses thereof
  申请人：——

  公开号：US20040072849A1

  公开（公告）日：2004-04-15

  In recognition of the need to develop novel therapeutic agents and efficient methods for the synthesis thereof, the present invention provides novel compounds of general formula (I): 1 and pharmaceutically acceptable derivatives thereof, wherein R 1 , R 2 , R 3 , n, X and Y are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier. The present invention further provides compounds capable of inhibiting histone deacetylatase activity and methods for treating disorders regulated by histone deacetylase activity (e.g., cancer and protozoal infections) comprising administering a therapeutically effective amount of a compound of formula (I) to a subject in need thereof. The present invention additionally provides methods for modulating the glucose-sensitive subset of genes downstream of Ure2p. The present invention also provides methods for preparing compounds of the invention.

  鉴于需要开发新型治疗剂和有效的合成方法，本发明提供了一般式(I)的新化合物： 1 及其药学上可接受的衍生物，其中R 1 ，R 2 ，R 3 ，n，X和Y如本文所定义。本发明还提供了包含一种式(I)化合物和药学上可接受的载体的药物组合物。本发明还提供了能够抑制组蛋白去乙酰化酶活性的化合物以及治疗由组蛋白去乙酰化酶活性调节的疾病的方法（例如，癌症和原虫感染），包括向需要的受体施用一种式(I)化合物的治疗有效量。本发明还提供了调节Ure2p下游葡萄糖敏感基因子集的方法。本发明还提供了制备本发明化合物的方法。
• NOVEL ISOXAZOLE DRIVATIVE
  申请人：Ishikawa Makoto

  公开号：US20110065739A1

  公开（公告）日：2011-03-17

  Disclosed is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, which has an agonistic activity on GPR120 and is therefore useful for the treatment of diabetes, obesity or hyperlipemia. [In formula (I), the A represents a phenyl group which may be substituted by a lower alkoxy group or the like; the 13 represents a bivalent group produced by removing two hydrogen atoms from a benzene ring which may be substituted by a halogen atom or the like; X represents a lower alkylene group having 2 to 4 carbon atoms in its main chain or the like, wherein a carbon atom constituting the main chain may be substituted by an oxygen atom or the like; and Y represents a hydrogen atom or the like.]

  揭示了一种由式(I)表示的化合物或其药学上可接受的盐，该化合物对GPR120具有激动活性，因此对于治疗糖尿病、肥胖或高脂血症是有用的。【在式(I)中，A代表可能被低烷氧基或类似物取代的苯基；13代表通过从苯环中去除两个氢原子而产生的二价基团，该苯环可能被卤素原子或类似物取代；X代表具有2至4个碳原子的低烷基基团或类似物，其中构成主链的碳原子可能被氧原子或类似物取代；Y代表氢原子或类似物。】
• HISTONE DEACETYLASE INHIBITORS
  申请人：Bradner James Elliot

  公开号：US20100056588A1

  公开（公告）日：2010-03-04

  In recognition of the need to develop novel therapeutic agents, the present invention provides novel histone deacetylase inhibitors. These compounds include an ester bond making them sensitive to deactivation by esterases. Therefore, these compounds are particularly useful in the treatment of skin disorders. When the compounds reaches the bloodstream, an esterase or an enzyme with esterase activity cleaves the compound into biologically inactive fragments or fragments with greatly reduced activity Ideally these degradation products exhibit a short serum and/or systemic half-life and are eliminated rapidly. These compounds and pharmaceutical compositions thereof are particularly useful in treating cutaneous T-cell lymphoma, neurofibromatosis, psoriasis, hair loss, skin pigmentation, and dermatitis, for example. The present invention also provides methods for preparing compounds of the invention and intermediates thereto.

  为了开发新型治疗剂，本发明提供了新型组蛋白去乙酰化酶抑制剂。这些化合物包括酯键，使它们对酯酶的失活敏感。因此，这些化合物在治疗皮肤疾病方面特别有用。当这些化合物进入血液循环时，酯酶或具有酯酶活性的酶将其裂解成生物学上不活性的碎片或具有大大降低活性的碎片。理想情况下，这些降解产物表现出短的血清和/或系统半衰期，并迅速被排出体外。这些化合物及其制剂在治疗切除性T细胞淋巴瘤、神经纤维瘤、银屑病、脱发、皮肤色素沉着和皮炎等方面特别有用。本发明还提供了制备本发明化合物及其中间体的方法。
• Laulimalide Analogs and Uses Thereof
  申请人：Gallagher Jr M. Brian

  公开号：US20070287745A1

  公开（公告）日：2007-12-13

  The present invention provides compounds having formula I: and pharmaceutically acceptable derivatives thereof, wherein R 1 -R 10 , q, t, X 0 , X 1 , A, B, D, E, G, J, K, L, M and Z are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders associated with cellular hyperproliferation.

  本发明提供具有公式I的化合物及其药学上可接受的衍生物，其中R1-R10、q、t、X0、X1、A、B、D、E、G、J、K、L、M和Z如本文中一般和在类别和子类别中所述，并且此外还提供其药物组合物以及使用它们治疗与细胞过度增殖相关的疾病的方法。
• COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Elder Amy

  公开号：US20110144090A1

  公开（公告）日：2011-06-16

  Indole compounds are disclosed. Also disclosed are methods for using the compounds to treat human and animal disease, pharmaceutical compositions of the compounds, and kits including the compounds.

  揭示了吲哚化合物。还揭示了使用该化合物治疗人类和动物疾病的方法，该化合物的药物组成以及包括该化合物的试剂盒。